WO1999016448A1 - Comprime de theophylline a liberation prolongee - Google Patents
Comprime de theophylline a liberation prolongee Download PDFInfo
- Publication number
- WO1999016448A1 WO1999016448A1 PCT/JP1998/004247 JP9804247W WO9916448A1 WO 1999016448 A1 WO1999016448 A1 WO 1999016448A1 JP 9804247 W JP9804247 W JP 9804247W WO 9916448 A1 WO9916448 A1 WO 9916448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- theophylline
- sustained
- granules
- coated
- coating
- Prior art date
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims abstract description 122
- 229960000278 theophylline Drugs 0.000 title claims abstract description 61
- 238000013268 sustained release Methods 0.000 title claims abstract description 11
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 11
- 239000011248 coating agent Substances 0.000 claims abstract description 64
- 239000007931 coated granule Substances 0.000 claims abstract description 57
- 239000008187 granular material Substances 0.000 claims abstract description 41
- 238000000576 coating method Methods 0.000 claims abstract description 38
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 16
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 10
- 239000004033 plastic Substances 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 31
- 239000007939 sustained release tablet Substances 0.000 claims description 17
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 7
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 7
- 239000001069 triethyl citrate Substances 0.000 claims description 7
- 235000013769 triethyl citrate Nutrition 0.000 claims description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
- 229960000541 cetyl alcohol Drugs 0.000 claims description 6
- -1 glycerin fatty acid ester Chemical class 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000008199 coating composition Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000002861 polymer material Substances 0.000 claims 1
- 229920003176 water-insoluble polymer Polymers 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 description 15
- 238000007922 dissolution test Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 5
- 235000013539 calcium stearate Nutrition 0.000 description 5
- 239000008116 calcium stearate Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000007908 dry granulation Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- FXPVUWKFNGVHIZ-UHFFFAOYSA-L disodium;dodecyl sulfate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O FXPVUWKFNGVHIZ-UHFFFAOYSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a theophylline sustained release tablet, and more particularly to a multiunit type sustained release tablet.
- Theophylline is a useful drug commonly used as a symptomatic agent for bronchial asthma, and its effective blood concentration range is known to be about 10 to 20 ⁇ g / ml.
- the difference between the medium and large concentrations is large, and is greatly affected by various conditions (heart failure, liver, kidney disease, etc.), age differences, and smoking status.
- theophylline has a short biological half-life of about 6 hours in adults and requires four doses a day to maintain effective blood levels. Multiple doses can be cumbersome for the patient, reduce patient compliance and exacerbate the condition.
- sustained-release theophylline preparations have medicinal ingredients dispersed in a matrix made of insoluble synthetic resin or lipid.
- JP98 / 04247 A type that provides a sustained release eg, Japanese Patent Application Laid-Open No. 56-122321, US Pat. No. 4,590,062
- capsules and tablets Of small particles (beads) having a release rate that is lower than that of the active ingredient and a layer of an insoluble lipid layer alternately formed around the nucleus.
- Patent No. 3,872,998 Some of these theophylline sustained-release preparations are already on the market, but each has drawbacks that cannot be ignored in practical use.Each type is still a complete sustained-release preparation. It is hard to call it a thing.
- the ratio of the carrier and excipients for dispersing the active ingredient reaches 50% or more, so that the content of the active ingredient and the size of the tablet cannot be reduced, and
- the disadvantage is that the release of the components is incomplete.
- the latter type of preparation has drawbacks such as requiring a high degree of skill because of the complicated operation required for its preparation, and increasing the production cost.
- an object of the present invention is to provide a multi-unit type preparation which is sufficient for one single administration and which is easy to prepare.
- the inventors of the present invention have conducted intensive studies in order to achieve such an object. As a result, the size of the tablet can be made smaller than that of a conventional theophylline preparation, and a superior sustained release effect can be obtained. The present inventors have found that a tablet having the same is obtained, and have completed the present invention.
- elementary granules mainly composed of theophylline are obtained. 7 Coated granules that are coated one or more times with a coating film composed of a hydrophobic substance and a plastic excipient, or a coating film further containing an enteric polymer substance. There is also provided a theophylline sustained-release tablet characterized in that the coated granules are compression-molded together with a disintegrating excipient.
- FIG. 1 is a graph showing the results of a dissolution test of the A-1.5 tablets to C-1.5 tablets obtained in Example 1 (the second method, 50 rotations, two liquids in Japan).
- FIG. 2 is a graph showing the results of a dissolution test (the second method, 50 rotations, two liquids of Japanese Pharmacopoeia) of each tablet obtained in Example 2 and Example 4.
- Fig. 3 is a graph showing the results of the dissolution test (Method 2, 50 and 100 rotations, JP 2 liquid) of the C-1.5 tablets and D-1.5 tablets obtained in Examples 1 and 3.
- FIG. 1 is a graph showing the results of the dissolution test (Method 2, 50 and 100 rotations, JP 2 liquid) of the C-1.5 tablets and D-1.5 tablets obtained in Examples 1 and 3.
- FIG. 1 is a graph showing the results of the dissolution test (Method 2, 50 and 100 rotations, JP 2 liquid) of the C-1.5 tablets and D-1.5 tablets obtained in Examples 1 and 3.
- FIG. 5 is a graph showing the dissolution behavior of G-1.5 tablets predicted from the dissolution test results of 1.5 tablets and F-1.5 tablets.
- FIG. 5 is a graph showing the results of the dissolution test of the H tablet and the I tablet obtained in Example 8 (Method 2, 50 rotations, JP 1 solution and JP 2 liquid).
- the elemental granules mainly composed of theophylline used in the present invention are relatively hard particles composed mostly of theophylline in the elementary granules, and preferably have a particle diameter of 50 to 170. 0 ⁇ m, more preferably P / JP98 / 04247
- the elementary granules are, for example, theophylline and a lubricating agent such as, for example, magnesium stearate, calcium stearate, light anhydrous maleic acid, hydrated silicon dioxide, and, for example, lauryl sulfate. It consists of a solubilizing agent such as sodium, sucrose fatty acid ester, and glyceryl monostearate, and the ratio of lubricant and solubilizer to 100 parts by weight of theophylline is about Less than 1 part by weight is sufficient.
- Elementary granules mainly composed of theophylline can be prepared, for example, by a general dry granulation method after uniformly mixing these powders.
- a coating agent for forming a coating film or a coating layer for coating elementary granules mainly composed of theophylline is contained in 100 parts by weight of a solvent such as a lower alcohol such as ethanol.
- a solvent such as a lower alcohol such as ethanol.
- the hydrophobic substance is 3 to 10 parts by weight, more preferably 3 to 8 parts by weight
- the plastic excipient is 100 to 100 parts by weight of the hydrophobic substance, preferably 10 to 10 parts by weight. It can be prepared by mixing and dispersing 50 parts by weight, more preferably 10 to 30 parts by weight, and a hydrophobic substance is preferably used for 100 parts by weight of a solvent such as a lower alcohol.
- Examples thereof include ethyl cellulose, methyl methacrylate acrylate copolymer or aminoalkyl methacrylate copolymer, and preferably ethyl cellulose or ethyl methacrylate acrylate copolymer.
- Methyl acid copolymers can be mentioned.
- plastic excipient for example, triethyl citrate, glycerin fatty acid esters, cetanol, hydrogenated castor oil, hydrogenated rapeseed oil, carnapalow, and the like can be used. Can be used.
- enteric polymer examples include, for example, copolymers of methacrylic acid, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate, succinate, carboxymethylethylcellulose and phthalic acid acetate.
- Cellulose can be used
- metaacrylic acid copolymer or hydroxypropyl methylcellulose phthalate preferably metaacrylic acid copolymer or hydroxypropyl methylcellulose phthalate.
- formation of a coating layer on the core material, theophylline granules, using the coating agent can be carried out by a known ordinary coating method.
- Spray coating can be performed by a coating method or the like.
- the coating agent for coating the theophylline granules can be coated in one or more layers, and generally, it is preferable to coat in two layers.
- granules coated with an aqueous coating agent may be further coated with an alcohol-based coating agent, or may be coated again with an alcohol-based coating agent and then re-coated.
- P98 / 04247 Can be coated with an alcohol-based coating agent. It is desirable to coat with an aqueous coating agent after coating with an aqueous coating agent.
- the coated granules thus obtained have a coating amount of preferably 5 to 50 parts by weight, more preferably 10 to 30 parts by weight, based on 100 parts by weight of theophylline-based granules. Have.
- the coated granules coated with the coating agent are preferably 1 to 25 parts by weight, more preferably 5 to 15 parts by weight, based on 100 parts by weight of theophylline in the coated granules.
- Tablets are used in tablets by conventional methods together with parts by weight of disintegrating excipients.
- the coated granules to be used for tableting may be a mixture of two or more different types of coated granules, such as those having different coating amounts and those having different coating compositions and number of layers.
- Disintegrating excipients that can be used in the present invention include, for example, corn starch, low-substituted hydroxypropylcellulose, croscarmellose sodium, carboxymethyl starch sodium, and the like.
- the disintegrating excipient may be used in the form of a powder or a granule having a particle diameter of 50 to 170) tm by, for example, a dry granulation method.
- the theophylline sustained-release tablet of the present invention is characterized in that when subjected to an in vitro dissolution test, it disintegrates and disperses into the original coated granules immediately after the test starts, and theophylline is gradually released from the disintegrated and dispersed coated granules. It is eluted at a time and shows sustained release. Further, in the theophylline sustained-release tablet of the present invention, theophylline mainly elutes from a broken portion such as a crack formed in the coating when the coated granules are compressed, and the elution is the stirring strength in the elution test. It is characterized in that it is hardly affected by compression and hardly affected by tableting pressure.
- the elution of theophylline from the theophylline sustained release tablet of the present invention can be performed by changing the composition of the coating agent, the coating amount of the coating agent, and the mixing ratio of the coated granules having different coating amounts. It can be adjusted to a reasonable speed.
- the theophylline sustained release tablet of the present invention is obtained by coating elementary granules mainly composed of theophylline with a small amount of a coating agent, and coating the resulting coated granules with a small amount of a disintegrating excipient (preferably theophylline). (1 to 25 parts by weight with respect to 100 parts by weight of phosphorus) and is not necessarily required to contain other additives. And has the advantage of being compact.
- theophylline sustained-release tablet of the present invention can easily adjust the rate of theophylline dissolution as appropriate, when actually administered to a human, the blood concentration of theophylline immediately after administration is reduced.
- Example 1 the present invention will be described specifically with reference to Examples, but it goes without saying that the scope of the present invention is not limited to these Examples.
- Example 1 the present invention will be described specifically with reference to Examples, but it goes without saying that the scope of the present invention is not limited to these Examples.
- Example 1 Using the coated granules obtained in Example 1 (7) and the granules obtained in Example 1 (8), the tableting pressure was increased to 1.0 t and 2.0 t in the same manner as in Example (11). The tablets were changed and pressed to obtain tablets (C-1.0 tablets, C-2.0 tablets).
- Example 1 After uniformly mixing 107 g of the coated granules obtained in Example 1 (4) and 10 g of the granules obtained in Example 1 (8), the mixture was mixed at 1.5 t using a modified punch. The tablets were compressed to give tablets (D-1.5 tablets) weighing 5884 mg, having a major axis of 13 mm, a minor axis of 6.5 mm, and a thickness of 6.73 mm.
- Example 5 Using the coated granules obtained in Example 1 (4) and the granules obtained in Example 1 (8), the tableting pressure was changed to 1.0 t and 2.0 t in the same manner as in Example 3. Each tablet (D-1.0 tablet, D-2.0 tablet) was obtained by tableting. / 04247 Example 5
- Example 1 (1) To 300 g of the elementary granules obtained in Example 1 (1), 100 g of the coating agent was sprayed in the same manner as in Example 1 (2) to obtain coated granules.
- a coating agent (390 g) was sprayed on 300 g of the coated granules obtained in (1) in the same manner as in Example 1 (5) to prepare coated granules coated in two layers.
- Example 1 (1) A coating agent (360 g) was sprayed on 300 g of the elementary granules obtained in Example 1 (1) in the same manner as in Example 1 (2) to obtain coated granules.
- a coating agent (390 g) was sprayed on 300 g of the coated granules obtained in (1) in the same manner as in Example 1 (5) to prepare coated granules coated in two layers.
- Example 8 91.1 g of the coated granules obtained in Example 5 (2), 105 g of the coated granules obtained in Example 6 (2) and 20 g of the granules obtained in Example 1 (8) were uniformly mixed. After that, this mixture is tabletted with a deformed punch at 1.5 t to obtain a tablet (weight: 54 lmg, major axis: 13 mm, minor axis: 6.5 mm, thickness: 6.01 mm) (G-1.5 Tablets).
- Example 8 91.1 g of the coated granules obtained in Example 5 (2), 105 g of the coated granules obtained in Example 6 (2) and 20 g of the granules obtained in Example 1 (8) were uniformly mixed. After that, this mixture is tabletted with a deformed punch at 1.5 t to obtain a tablet (weight: 54 lmg, major axis: 13 mm, minor axis: 6.5 mm, thickness: 6.01 mm) (G-1.5 Tablets).
- Hydroxypropylmethylcellulose phthalate (HP-50) and 300 g of a coating agent of the following composition using cetanol were further coated with a fluidized bed granulation coating device, and double coated.
- the prepared coated granules were prepared.
- JP Japanese Pharmacopoeia, 13th Edition
- the tablets prepared in the examples were used as samples, and the 2nd solution of the Japanese Pharmacopoeia Disintegration Test ( The dissolution test was performed using “JP2 solution”. After the test was started, the eluate of each sample was collected over time. After diluting the collected liquid with 0.1 N hydrochloric acid, the absorbance at 271 nm was measured, and the elution rate was calculated. The obtained results are shown in FIGS.
- the sustained-release tablet of theophylline according to the present invention is not easily affected by the tableting pressure during production or the stirring intensity during the dissolution test, and has a stable theophylline dissolution rate. . Furthermore, the elution rate of theophylline can be appropriately adjusted to the target elution rate by adjusting the mixing ratio of two or more types of coated granules having different coating compositions and coating amounts. -It is possible to design a two-dose preparation. Also, compared to conventional multiple-unit type tablets, they can be prepared with a relatively simple formulation and do not necessarily require additives other than disintegrating excipients. it can.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98943075A EP1025848A4 (en) | 1997-09-30 | 1998-09-21 | THEOPHYLLINE TABLET WITH PROLONGED RELEASE |
US09/509,322 US6426091B1 (en) | 1997-09-30 | 1998-09-21 | Sustained-release theophylline tablet |
CA002304110A CA2304110C (en) | 1997-09-30 | 1998-09-21 | Theophylline sustained release tablet |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28117297 | 1997-09-30 | ||
JP9/281172 | 1997-09-30 | ||
JP23540698A JP3611456B2 (ja) | 1997-09-30 | 1998-08-21 | テオフィリン徐放性錠剤 |
JP10/235406 | 1998-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999016448A1 true WO1999016448A1 (fr) | 1999-04-08 |
Family
ID=26532107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004247 WO1999016448A1 (fr) | 1997-09-30 | 1998-09-21 | Comprime de theophylline a liberation prolongee |
Country Status (7)
Country | Link |
---|---|
US (1) | US6426091B1 (ja) |
EP (1) | EP1025848A4 (ja) |
JP (1) | JP3611456B2 (ja) |
KR (1) | KR100371523B1 (ja) |
CN (1) | CN1170540C (ja) |
CA (1) | CA2304110C (ja) |
WO (1) | WO1999016448A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1207860A4 (en) * | 1999-09-02 | 2005-07-13 | Nostrum Pharmaceuticals Inc | PASTILLE TYPE FORMULATION WITH CONTROLLED RELEASE |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6228799A (en) | 1998-10-26 | 2000-05-15 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
JP2000198747A (ja) * | 1998-10-26 | 2000-07-18 | Tanabe Seiyaku Co Ltd | 徐放性粒子 |
IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
JP2002179571A (ja) * | 2000-12-11 | 2002-06-26 | Nikken Chem Co Ltd | 小型徐放性錠剤 |
JP4310605B2 (ja) | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
JPWO2003032998A1 (ja) * | 2001-10-15 | 2005-02-03 | 三菱ウェルファーマ株式会社 | 徐放性微粒子及びその製造方法 |
US20030190343A1 (en) * | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
ITMI20030616A1 (it) * | 2003-03-28 | 2004-09-29 | Acme Drugs S R L | Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente |
CA2529475C (en) * | 2003-06-27 | 2012-08-07 | Otsuka Pharmaceutical Co., Ltd. | Medicament sustained-release particles and method for preparing the same |
CA2560613C (en) * | 2004-03-22 | 2015-11-24 | Solvay Pharmaceuticals Gmbh | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
WO2007014896A1 (en) * | 2005-07-29 | 2007-02-08 | Solvay Pharmaceuticals Gmbh | Processes for the manufacture of sterilized pancreatin powder |
DE602006012346D1 (de) * | 2005-08-15 | 2010-04-01 | Solvay Pharm Gmbh | Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9198871B2 (en) * | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
SI1931316T2 (sl) * | 2005-08-15 | 2017-05-31 | Abbott Laboratories Gmbh | Farmacevtski sestavki z nadzorovanim sproščanjem za kislinsko labilna zdravila |
NZ569984A (en) * | 2006-01-27 | 2011-06-30 | Eurand Inc | Drug delivery systems comprising weakly basic drugs and organic acids |
US10072256B2 (en) * | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
CA2677989C (en) | 2007-02-20 | 2018-04-24 | Eurand Pharmaceuticals Limited | Stable digestive enzyme compositions |
US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
EP2588589B2 (en) | 2010-07-02 | 2023-07-19 | The Procter & Gamble Company | Process for the production of a detergent product |
BR112013000101A2 (pt) | 2010-07-02 | 2016-05-17 | Procter & Gamble | filamentos compreendendo mantas de não tecido com agente ativo e métodos de fabricação dos mesmos |
CA2803382C (en) | 2010-07-02 | 2015-03-31 | The Procter & Gamble Company | Method for delivering an active agent |
MX348118B (es) | 2010-10-01 | 2017-05-26 | Aptalis Pharma Ltd | Formulaciones de pancrelipasa con recubrimiento enterico de baja potencia. |
JP6158801B2 (ja) | 2011-07-15 | 2017-07-05 | ニューサート サイエンシーズ, インコーポレイテッド | 代謝経路を変調させるための組成物および方法 |
EP2987499B1 (en) | 2011-08-08 | 2019-05-08 | Allergan Pharmaceuticals International Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
AU2014207707B2 (en) | 2013-01-15 | 2018-11-01 | Nusirt Sciences, Inc. | Treating pulmonary conditions |
AU2014236687A1 (en) | 2013-03-15 | 2015-09-10 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
RU2679832C2 (ru) | 2013-08-09 | 2019-02-13 | Аллерган Фармасьютикалз Интернэйшнл Лимитед | Композиция пищеварительных ферментов, подходящая для энтерального введения |
CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
JP7381613B2 (ja) | 2019-06-28 | 2023-11-15 | ザ プロクター アンド ギャンブル カンパニー | アニオン性界面活性剤を含有する溶解性固体繊維性物品 |
WO2022027067A1 (en) | 2020-07-31 | 2022-02-03 | The Procter & Gamble Company | Water-soluble fibrous pouch containing prills for hair care |
WO2022125007A1 (en) * | 2020-12-08 | 2022-06-16 | Santa Farma Ilac Sanayii A. S. | Prolonged release mirabegron formulations |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02138210A (ja) * | 1988-08-22 | 1990-05-28 | Ss Pharmaceut Co Ltd | 圧縮成型製剤 |
JPH03190817A (ja) * | 1989-12-01 | 1991-08-20 | Abbott Lab | 徐放性調剤単位 |
JPH03193734A (ja) * | 1989-12-22 | 1991-08-23 | Eisai Co Ltd | 徐放性固形製剤 |
JPH03193733A (ja) * | 1989-12-25 | 1991-08-23 | Nikken Chem Co Ltd | テオフィリンの徐放性製剤 |
JPH06293635A (ja) * | 1993-04-08 | 1994-10-21 | Amano Pharmaceut Co Ltd | 耐衝撃性腸溶性顆粒剤およびこれを含む錠剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791458A (fr) | 1972-07-31 | 1973-05-16 | Merck & Co Inc | Produit microencapsule |
JPS56122311A (en) | 1980-02-29 | 1981-09-25 | Eisai Co Ltd | Lasting theophylline pharmaceutical composition |
JPS5753325A (en) | 1980-09-16 | 1982-03-30 | Kobe Steel Ltd | Stretching device for plastic film etc |
DE3435325A1 (de) * | 1983-04-09 | 1986-04-17 | Nikken Chemicals Co., Ltd., Tokio/Tokyo | Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung |
US4590062A (en) | 1984-04-16 | 1986-05-20 | Tech Trade Corp. | Dry direct compression compositions for controlled release dosage forms |
JP2700662B2 (ja) * | 1988-06-22 | 1998-01-21 | 大正製薬株式会社 | 被覆製剤 |
US5169642A (en) | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
US5268182A (en) | 1988-06-24 | 1993-12-07 | Abbott Laboratories | Sustained-release drug dosage units of terazosin |
JP2893191B2 (ja) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
JP3193733B2 (ja) | 1990-04-16 | 2001-07-30 | ユニ・チャーム株式会社 | 使い捨て体液処理用品の不透液性防漏シート |
JP3193734B2 (ja) | 1991-07-15 | 2001-07-30 | 松下電工株式会社 | 可変色照明システム |
JPH0729927A (ja) | 1993-07-07 | 1995-01-31 | Hitachi Ltd | 半導体集積回路装置の製造方法 |
JP3190817B2 (ja) | 1996-02-19 | 2001-07-23 | 株式会社小糸製作所 | 灯 具 |
-
1998
- 1998-08-21 JP JP23540698A patent/JP3611456B2/ja not_active Expired - Fee Related
- 1998-09-21 EP EP98943075A patent/EP1025848A4/en not_active Withdrawn
- 1998-09-21 KR KR10-2000-7003061A patent/KR100371523B1/ko not_active IP Right Cessation
- 1998-09-21 CN CNB98809696XA patent/CN1170540C/zh not_active Expired - Fee Related
- 1998-09-21 WO PCT/JP1998/004247 patent/WO1999016448A1/ja not_active Application Discontinuation
- 1998-09-21 US US09/509,322 patent/US6426091B1/en not_active Expired - Fee Related
- 1998-09-21 CA CA002304110A patent/CA2304110C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02138210A (ja) * | 1988-08-22 | 1990-05-28 | Ss Pharmaceut Co Ltd | 圧縮成型製剤 |
JPH03190817A (ja) * | 1989-12-01 | 1991-08-20 | Abbott Lab | 徐放性調剤単位 |
JPH03193734A (ja) * | 1989-12-22 | 1991-08-23 | Eisai Co Ltd | 徐放性固形製剤 |
JPH03193733A (ja) * | 1989-12-25 | 1991-08-23 | Nikken Chem Co Ltd | テオフィリンの徐放性製剤 |
JPH06293635A (ja) * | 1993-04-08 | 1994-10-21 | Amano Pharmaceut Co Ltd | 耐衝撃性腸溶性顆粒剤およびこれを含む錠剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1025848A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1207860A4 (en) * | 1999-09-02 | 2005-07-13 | Nostrum Pharmaceuticals Inc | PASTILLE TYPE FORMULATION WITH CONTROLLED RELEASE |
Also Published As
Publication number | Publication date |
---|---|
KR20010024239A (ko) | 2001-03-26 |
CA2304110C (en) | 2004-03-30 |
CN1170540C (zh) | 2004-10-13 |
CA2304110A1 (en) | 1999-04-08 |
EP1025848A4 (en) | 2006-06-21 |
JP3611456B2 (ja) | 2005-01-19 |
KR100371523B1 (ko) | 2003-02-07 |
US6426091B1 (en) | 2002-07-30 |
JPH11171775A (ja) | 1999-06-29 |
CN1272787A (zh) | 2000-11-08 |
EP1025848A1 (en) | 2000-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999016448A1 (fr) | Comprime de theophylline a liberation prolongee | |
AU781058B2 (en) | Delayed-action form of administration containing tramadol saccharinate | |
AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
JP2514078B2 (ja) | 圧縮成型製剤 | |
JPH0772129B2 (ja) | 持続放出性複合単位製剤 | |
US20230240994A1 (en) | Medicament-containing hollow particle | |
JPH0251402B2 (ja) | ||
JPS6327424A (ja) | 徐放性製剤およびその製造法 | |
JP2005512997A (ja) | タムスロシン錠 | |
US20050226927A1 (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist | |
CZ20012201A3 (cs) | Přípravek s řízeným uvolňováním obsahující divalproex sodný | |
AU2009247921B2 (en) | Solid oral form with dual release profile, containing multiparticulates | |
US20140044780A1 (en) | Extended-Release Levetiracetam and Method of Preparation | |
JP2009191034A (ja) | 時限放出製剤 | |
JP2007531727A (ja) | Gabab受容体アゴニストを含有する即時放出特性および/または制御放出特性を有する薬学的剤形 | |
JPH04234812A (ja) | 持続性製剤用顆粒 | |
US20090136550A1 (en) | Modified release formulations of diltiazem | |
KR102104507B1 (ko) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 | |
JP3929522B2 (ja) | 難水溶性薬物の徐放性製剤 | |
JP4494712B2 (ja) | マルチプルユニット型徐放性製剤 | |
US20050220863A1 (en) | Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist | |
US20050220874A1 (en) | Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist | |
JP2002179571A (ja) | 小型徐放性錠剤 | |
WO2023182332A1 (ja) | 口腔内崩壊錠用の添加剤組成物 | |
WO2004024138A1 (ja) | ジオクチルソジウムスルホサクシネート配合固形製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98809696.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2304110 Country of ref document: CA Ref document number: 2304110 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09509322 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007003061 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998943075 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998943075 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007003061 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007003061 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998943075 Country of ref document: EP |